Skip to main content

Table 3 Final population parameter estimates of mefloquine with their bootstrap evaluations in 2000 replicates

From: Population pharmacokinetics and pharmacodynamics of the artesunate–mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children

Population pharmacokinetics analysis Bootstrap evaluation
Parameter Estimate RSE (%)a BSV (%)b RSE (%)a Estimate CI95% c BSV (%)b CI95% c
F1 1 FIX   28 15 1 FIX   27 18 to 34
CL (L/h)d 0.45 7 39 17 0.45 0.39 to 0.51 38 24 to 51
VC (L)d 95 7    92 66 to 106   
Ka (h−1) DAY = 1 0.17 17 91 12 0.16 0.10 to 0.23 87 64 to 110
Ka (h−1) DAY > 1 0.40 22 0.38 0.22 to 0.64
θAGE Ka − 0.67 18    − 0.66 − 0.91 to − 0.29   
Q (L/h)d 0.35 28    0.35 0.24 to 1.30   
VP(L)d 60 9    61 51 to 82   
σprop (CV %) 21 13    20 14 to 26   
  1. F1, bioavailability; CL, clearance; VC, central volume of distribution; Ka, first-order absorption rate constant; Q, intercompartmental clearance; VP, peripheral volume of distribution; σprop, exponential residual error; θAGE Ka, effect of AGE on Ka expressed as (1 + θAGE Ka (AGE–AGE)/MAGE) with MAGE = 2.6 years; median AGE value in the study population
  2. aRelative standard error (RSE) of the estimate defined as SE estimate/estimate, expressed as a percentage, with SE estimate retrieved directly from the NONMEM output file
  3. bBetween-subject variability
  4. c95% confidence interval (CI)
  5. dPharmacokinetic parameter of a patient of 12.2 kg, the median population body weight (MBW). Individual clearance, peripheral clearance and volumes of distribution are obtained by the equations: CLM,ind = CL*(BW/MBW)0.75, QM,ind = Q*(BW/MBW)0.75, VC,ind = VC * BW/MBW, and VP,ind = VP * BW/MBW, respectively, with BW patient’s body weight